The Challenge of Targeting Notch in Hematologic Malignancies
Open Access
- 10 June 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 2, 54
Abstract
Notch signaling can play oncogenic and tumor suppressor roles depending on cell type. Hematologic malignancies encompass a wide range of transformed cells, and consequently the roles of Notch are diverse in these diseases. For example Notch is a potent T cell oncogene, with >50% of T cell acute lymphoblastic leukemia (T-ALL) cases carry activating mutations in the Notch1 receptor. Targeting Notch signaling in T-ALL with gamma secretase inhibitors, which prevent Notch receptor activation, has shown pre-clinical activity, and is under evaluation clinically. In contrast, Notch signaling inhibits acute myeloblastic leukemia growth and survival, and although targeting Notch signaling in AML with Notch activators appears to have pre-clinical activity, no Notch agonists are clinically available at this time. As such, despite accumulating evidence about the biology of Notch signaling in different hematologic cancers, which provide compelling clinical promise, we are only beginning to target this pathway clinically, either on or off. In this review we will summarize the evidence for oncogenic and tumor suppressor roles of Notch in a wide range of leukemias and lymphomas, and describe therapeutic opportunities for now and the future.Keywords
This publication has 102 references indexed in Scilit:
- Epigenetic Inactivation of Notch-Hes Pathway in Human B-Cell Acute Lymphoblastic LeukemiaPLOS ONE, 2013
- Notch2 inhibits proliferation of chronic myeloid leukemia cellsOncology Letters, 2013
- Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cellsMethods, 2012
- Notch signaling in human development and diseaseSeminars in Cell & Developmental Biology, 2012
- Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutationsBlood Cancer Journal, 2012
- Notch pathway activation induces neuroblastoma tumor cell growth arrestPediatric Blood & Cancer, 2011
- Notch signalling in T‐cell lymphoblastic leukaemia/lymphoma and other haematological malignanciesThe Journal of Pathology, 2010
- Direct inhibition of the NOTCH transcription factor complexNature, 2009
- NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemiaLeukemia, 2009
- The Canonical Notch Signaling Pathway: Unfolding the Activation MechanismCell, 2009